COMPANY
Seelos Therapeutics
Timeline
- Trial start Phase 2: SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease source ↗
- Trial start Phase 2/Phase 3: STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia source ↗
- Trial start Phase 2: A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05597436 | Intermediate-Sized Expanded Access Study | Not listed | No longer available | Not listed | Not listed |
| NCT05490563 | STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia | Phase 2/Phase 3 | Terminated | Jun 3, 2022 | Nov 24, 2023 (actual) |
| NCT04669665 | A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide | Phase 2 | Completed | Dec 17, 2020 | Jun 17, 2023 (actual) |
| NCT05332678 | SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease | Phase 2 | Withdrawn | Mar 3, 2023 | Apr 10, 2023 (actual) |
Connect
See your connections at Seelos Therapeutics on LinkedIn (search by name, results not checked)